Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients

Abstract

SummaryBackgroundBone marrow transplantation (BMT) is a standard treatment for several haematologic conditions. Following BMT, patients may develop hepatobiliary complications that impact morbidity and mortality. The differential diagnosis may include drug‐induced liver injury (DILI), sepsis‐associated liver injury (SALI), sinusoidal obstruction syndrome (SOS), graft‐versus‐host disease (GVHD), viral hepatitis, ischaemic hepatitis, and fulminant hepatitis.AimsTo evaluate the frequency, clinical characteristics, and outcomes of patients with hepatobiliary alterations associated with BMT in a tertiary referral centre.MethodsThis was a cross‐sectional study with data collected from the medical records of patients undergoing BMT between January 2017 and June 2022. We diagnosed hepatobiliary complications based on established criteria.ResultsWe included 377 patients; 55.7% had hepatobiliary complications. Female gender, pre‐BMT hepatobiliary alteration, and haploidentical allogeneic transplantation were associated with increased risk with odds ratios (OR) of 1.8 (p = 0.005), 1.72 (p = 0.013) and 3.25 (p = 0.003), respectively. Patients with hepatobiliary complications spent longer in the hospital than those without (27.7 × 19.3 days, respectively; p < 0.001). Among 210 patients with hepatobiliary complications, 28 died compared to 5 of 167 without complications (OR 4.98; p = 0.001).ConclusionsHepatobiliary complications are frequent in patients undergoing BMT. There is a greater risk of their occurrence in women, people with pre‐BMT liver alterations, and in haploidentical transplants. The occurrence of these complications increases the length of stay and is associated with a higher risk of death.